SCHEMBL13370751

SCHEMBL13370751

CNCCOP(=O)(O)OCCN

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLA2G2C Q5R387 1/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 2/20 0.37
BLM P54132 2/20 0.37
CYP3A4 P08684 1/20 0.37
NFKB1 P19838 1/20 0.37
PMP22 Q01453 1/20 0.37
GABBR2 O75899 4/20 0.34
GABBR1 Q9UBS5 4/20 0.34
CYP1A2 P05177 1/20 0.34
TSHR P16473 1/20 0.34
THPO P40225 1/20 0.34
PLA2G2D Q9UNK4 1/20 0.33
ITPR3 Q14573 1/20 0.33
ITPR1 Q14643 1/20 0.33
ANPEP P15144 1/20 0.32
BTN3A1 O00481 1/20 0.32
GABRR1 P24046 1/20 0.31
IGF2R P11717 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11408483 0.82 PLA2G2C (0.41) PLA2G2CALDH1A1LMNABLMCYP3A4
SCHEMBL13431174 0.82 PPARD (0.42) TSHRBTN3A1
SCHEMBL10240866 0.79 PLA2G2A (0.37) ANPEPBTN3A1
SCHEMBL19605920 0.77 BTN3A1 (0.41) ALDH1A1BTN3A1
SCHEMBL13978764 0.77 BBOX1 (0.44) LMNABLMNFKB1TSHR
SCHEMBL10025687 0.77 PLA2G2C (0.47) PLA2G2CCYP3A4GABBR2GABBR1PLA2G2D
SCHEMBL5454175 0.77 PLA2G2C (0.43) PLA2G2CGABBR2GABBR1CYP1A2TSHR
SCHEMBL637889 0.76
SCHEMBL23118552 0.76 SAT1 (0.41) BTN3A1
SCHEMBL14468612 0.76 LPAR3 (0.58) PLA2G2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10835612-B2 Lipids and compositions for the delivery of therapeutics ARBUTUS BIOPHARMA CORPORATION (CA) 2020-11-17 US disclosed
US-20180125985-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ARBUTUS BIOPHARMA CORPORATION (CA) 2018-05-10 US disclosed
US-20180064807-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ARBUTUS BIOPHARMA CORPORATION (CA) 2018-03-08 US disclosed
EP-3238738-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS Arbutus Biopharma Corporation (CA) 2017-11-01 EP disclosed
EP-2355658-B1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ARBUTUS BIOPHARMA CORP (CA) 2017-09-27 EP disclosed
US-9220683-B2 Lipids and compositions for the delivery of therapeutics TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2015-12-29 US disclosed
US-20120027796-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-02-02 US disclosed
WO-2010054406-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180125985-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS CETP, LCAT, NPC1L1 PLA2G2C 173/4885ALDH1A1 3880/4885LMNA 974/4885
US-20180064807-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS CETP, LCAT, NPC1L1 PLA2G2C 161/4885ALDH1A1 3847/4885LMNA 975/4885
US-10835612-B2 Lipids and compositions for the delivery of therapeutics CETP, LCAT, LIPA PLA2G2C 220/4885ALDH1A1 3248/4885LMNA 792/4885
US-20120027796-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS CETP, ABCB4, LCAT PLA2G2C 200/4885ALDH1A1 4201/4885LMNA 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.